Antiphospholipid antibodies and pregnancy outcomes in women heterozygous for Factor V Leiden

Department of Obstetrics and Gynecology, University of Utah, 30N 1900E, Room 2B200, Salt Lake City, UT 84132, USA.
Journal of Reproductive Immunology (Impact Factor: 2.82). 06/2010; 85(2):180-5. DOI: 10.1016/j.jri.2010.03.007
Source: PubMed


Antiphospholipid antibodies are associated with a spectrum of pregnancy complications, including preeclampsia and small for gestational age (SGA) fetuses. We sought to assess anticardiolipin and anti-beta2-glycoprotein I (anti-beta2-GPI) IgG and IgM antibody prevalence and the relationship of these antibodies to pregnancy complications in women with the Factor V Leiden (FVL) mutation. The study comprised a secondary analysis of a multicenter, prospective observational study of FVL prevalence among 5188 asymptomatic pregnant women. A subset of 362 women (117 FVL heterozygotes, 245 matched controls) had serum collected at the time of the original study and underwent serum analysis for anticardiolipin and anti-beta2-GPI IgG and IgM as a part of this analysis. The primary outcome was preeclampsia and/or SGA (<10%). The overall prevalence of anticardiolipin and anti-beta2-GPI IgG and IgM antibodies was low and did not vary with FVL status. Forty-seven women (13.0%) developed preeclampsia and/or SGA. There were no differences in primary outcome rates between women with and without aPL antibodies, regardless of FVL mutation status. Among FVL carriers, the presence of antiphospholipid antibodies does not appear to contribute to adverse pregnancy outcome.

Download full-text


Available from: Ronald Wapner,
32 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Knowledge of antiphospholipid antibodies and their impact on pregnancy continues to evolve. A variety of antiphospholipid antibodies have been identified, but not all of them seem to be pathologic for pregnancy outcome. Understanding of which patients are at high risk for adverse pregnancy outcome and the most effective treatment will require clinical trials based on risk stratification and long-term follow-up of infants.
    Clinics in laboratory medicine 06/2013; 33(2):367-376. DOI:10.1016/j.cll.2013.01.001 · 1.37 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We thank Drs. Kjellberg and Hellgren for their letter and for pointing out that the results of their study are consistent with our findings. Space limitations prevented us from more detailed reporting of the methods and results of our systematic review. We are familiar with the study by Kjellberg and colleagues as it was one of the seven full-text articles [1-7] that were retrieved in the systematic review process. Their report was independently assessed by two reviewers (MR, NL) then discussed, leading to the conclusion that the study was not eligible owing to its design. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
    Journal of Thrombosis and Haemostasis 06/2014; 12(8). DOI:10.1111/jth.12632 · 5.72 Impact Factor